Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight

Tokuchi, Yoshimasa; Suda, Goki; Kawagishi, Naoki; Ohara, Masatsugu; Kohya, Risako; Sasaki, Takashi; Yoda, Tomoka; Maehara, Osamu; Ohnishi, Shunsuke; Kubo, Akinori; Yoshida, Shuhei; Fu, Qingjie; Yang, Zijian; Hosoda, Shunichi; Kitagataya, Takashi; Suzuki, Kazuharu; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakamoto, Naoya

doi:10.1111/hepr.13899

Cited by 8 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, there was a tradeoff between glucose amelioration 25–27 and dyslipidemia 28 after HCV eradication. Furthermore, body weight gain 29 and the prevalence of fatty liver 30 have been reported to increase after HCV eradication. In addition, obesity has been viewed as a critical risk factor for persistent liver inflammation and liver disease progression after HCV eradication 31 .…”

Section: Discussionmentioning

confidence: 99%

The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

Huang,

Liang,

Tsai

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and AimThe prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive.MethodsA mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non‐MAFLD subjects with advanced liver disease.ResultsTwo thousand two hundred and forty‐two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti‐HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non‐viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, P < 0.001), male sex (OR/CI: 1.3/1.0–1.7, P = 0.019), anti‐HCV seropositivity (OR/CI: 5.9/4.6–7.5, P = 0.019), MAFLD‐lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3–5.2, P = 0.005; compared with the non‐MAFLD group) and MAFLD‐diabetes (OR/CI: 1.5/1.1–2.1, P = 0.008; compared with the non‐MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD‐lean MS group (OR/CI: 9.1/2.4–34.6, P = 0.001; compared with non‐MAFLD group) and MAFLD‐DM group (OR/CI: 2.0/1.2–3.2, P = 0.004; compared with non‐MAFLD group).ConclusionsMAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non‐viral hepatitis subjects in a community level.

show abstract

Section: Discussionmentioning

confidence: 99%

The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

Huang,

Liang,

Tsai

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Patients with MS, in particular those with DM, had a 3.03-fold higher risk of HCC compared to those without MS [ 21 ]. As increased body weight and hepatic steatosis have been reported after HCV eradication [ 22 ], the concurrence of steatotic liver disease should be incorporated with HCV infection with respect to holistic care in the post-SVR era [ 23 ] since it might be an independent risk factor for HCC after HCV eradication [ 24 , 25 ].…”

Section: Screening Targets and Hcc Surveillance Strategiesmentioning

confidence: 99%

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Huang,

Awad,

Gal-Tanamy

et al. 2024

Clin Mol Hepatol

View full text Add to dashboard Cite

List of abbreviationsAST: aspartate aminotransferase. AST:alanine aminotransferase. AFP: alpha fetoprotein. CHC: chronic hepatitis C. DAA: directly acting antiviral. FIB-4: fibrosis-4 index. HCV: hepatitis C virus. HCC: hepatocellular carcinoma. IFN: interferon. MICA: MHC class I chain-related A. SVR: sustained virological response. SNP: single nucleotide polymorphism Authors' contributions Conception and design: Ming-Lung Yu

show abstract

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Liu,

Chang,

Fang

et al. 2024

J Gastroenterol

View full text Add to dashboard Cite

Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight

Cited by 8 publications

References 55 publications

The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Contact Info

Product

Resources

About